Shin Ujiie
shin.ujiie.wg12@wharton.upenn.edu The University of Tokyo, Tokyo, Japan B.S., Agriculture, 2003 M.S., Agricultural Life Science
John A. Urquhart
john.urquhart.wg12@wharton.upenn.edu Brown University, Providence, RI A.B., Business Economics and Public and Private Sector Organization, 2004
Reed S. Van Gorden
reed.van.gorden.wg12@
wharton.upenn.edu Northwestern University, Evanston, IL B.A., Economics and Biological Sciences, 2006 CFA Charterholder, 2010
An opportunity to combine my experience and expertise in life science and business arenas to create value in the healthcare industry.
Eisai Co., Ltd., Tokyo, Japan Associate, 2005-2010 Conducted scientific and financial eval- uation of business development deals including in-licensing and out-licensing deals. Worked closely with researchers and business people to strategically streamline Eisai’s pipeline and establish Eisai’s mid- and long-term corporate plans. Led due diligence teams to acquire a $350M oncology focused biotechnology company, Morphotek Inc., and a $4B oncology focused specialized company, MGI Pharma. Established and organized R&D related committees such as Global Oncology Committee and Eisai Scientific Advisory Board. Served as one of organizers of Eisai’s supreme discussion body, Global Policy and Strategy Council, and decision making body, the Executive Committee of Eisai. Established Eisai’s new operation in diagnostic arena with Sanko Jyun- yaku, now a wholely-owned subsidiary of Eisai.
An opportunity to evaluate and invest in healthcare companies and technologies.
Celgene Corporation, Summit, NJ Summer Associate, Global Marketing Summer 2011 Worked within cross functional teams to identify global marketing best practices and implement value-add initiatives. Engaged outside expertise to improve treatment duration and patient adherence for oral oncology medicine. Developed action plan for building disease specific mobile application physician tool. Assessed commercial opportunity for indication expansion of existing product.
Cowen Healthcare Royalty Partners, Stamford, CT Associate, 2008-2010 Analyst, 2007 First investment professional hired by new private equity fund. Completed 9 transactions and invested over $300M in transactions of various struc- tures, including: royalty monetizations, synthetic royalty interests, structured debt and equity investments. Responsible for building valuation models, structuring investments and conducting due diligence. Prepared fundraising marketing materials and communicated with existing and prospective limited partners.
SG Cowen Securities, Boston, MA Investment Banking Analyst, 2004-2007 Created financial models and perform in-depth analysis of various transac- tions including buyside and sellside M&A and equity financings for variety of public and private technology/ software companies.
An opportunity to build successful healthcare companies through effective investment and management.
Actient Pharmaceuticals, Lake Forest, IL Intern, GTCR Portfolio Company Summer 2011 Evaluated the Urology/Gynecology landscape for viable opportunities – ranked 16 disease states across 8 metrics and identified potential development and acquisition targets in the top five disease states.
Genentech, San Francisco, CA Intern, Summer 2011 Executed CEO initiated cost-benefit analysis on sales meetings, clinical specialist days on-territory, and com- mercial travel expenses; conducted over 85 interviews throughout all levels of the sales division.
Abingworth Management, Waltham, MA Associate, 2008-2010 Provided Letter of Intent and led in-depth due diligence on 8 healthcare targets; completed two transactions. Streamlined due diligence process by establishing formal metrics for review, improving competitiveness in managed processes. Individually responsible for 33% of all GE deal flow; built deal network via cold-calling, networking and conferences. Built investment thesis around specific sub-sectors: HIT, Aesthetic Devices, Pathology and Molecular Laboratories.
J.P. Morgan, New York, NY Analyst, 2006-2008 Transactions: $37B LBO of Harrah’s Casinos; $7.3B LBO of CDW Corpora- tion; $7.1B LBO of Manor Care; $4.1B Revolving Credit Facility and $225M recapitalization for Patheon.
27
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40